Evofem Biosciences Inc

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO , July 29, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM), a women's healthcare company, today commended the U.S. Department of Health and Human Services, alongside the Departments of Labor and of the Treasury ("the Tri-Agencies"), for taking action to clarify protections for birth control coverage under the Affordable Care Act (ACA). "Yesterday, the United States took a critical step forward in protecting the right to contraception.

Evofem Biosciences Commends Tri-Agencies for Clarifying that Contraceptives Must be Covered at No Cost to Individuals

-- Conference Call Scheduled for 5:00 p.m. ET -- SAN DIEGO , July 28, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2022 as follows: Date: Thursday, August 4, 2022 Time: 5:00 pm.

Evofem Biosciences to Report Second Quarter 2022 Results and Provide Corporate Update on Thursday, August 4, 2022

Evocative direct-to-consumer (DTC) campaign has received 12 healthcare and communications industry awards to date and has recently been shortlisted for four more awards. The national campaign features Emmy ® Award-winning spokeswoman and actress Annie Murphy and was created to generate awareness of Evofem's hormone-free contraceptive, Phexxi, while also highlighting the contraceptive journey of millions of women, like Annie, who are tired of dealing with the side effects of hormones in their birth control.

Evofem's House Rules Campaign Featuring Annie Murphy Receives Significant Industry Recognition

SAN DIEGO , July 25, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it has developed a new educational birth control chart that provides high-level information about the different options available to women in the United States. "Contraceptive counseling is one of the most important aspects of a healthcare provider's job.

Evofem Biosciences Unveils New Educational Birth Control Chart to Assist Providers in Patient Contraceptive Counseling

SAN DIEGO , July 22, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM), a women's healthcare company, today applauded the 228 members of the U.S. House of Representatives who voted to pass legislation to safeguard access to contraceptives entitled The Right to Contraception Act. "Today we applaud the U.S. House of Representatives for passing The Right to Contraception Act, which would codify into law the fundamental right to safe and easy access to contraception," said Saundra Pelletier, Chief Executive Officer of Evofem Biosciences.

Evofem Biosciences Applauds U.S. House of Representatives for Passing The Right to Contraception Act

aTyr Pharma

22nd Century Group

Analysts say these are penny stocks to buy, do you agree? The post Best Penny Stocks to Buy Now According To 3 Top Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Now According To 3 Top Analysts

Agreement with a360 Media Delivers Phexxi Branded Content in Leading Entertainment and Lifestyle Magazines a360 Media's Brands Include US Magazine, InTouch Weekly, and Woman's World 16% Lift in New Phexxi Prescriptions After First Two Weeks of Partnership SAN DIEGO , July 21, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced an agreement between Evofem and a360 Media under which Phexxi® (lactic acid, citric acid, and potassium bitartrate) branded content will appear in some of the most widely read entertainment and lifestyle magazines and websites in the U.S. "We are thrilled to partner with a360 Media to raise awareness of Phexxi among the millions of women reading some of the most popular magazines and websites in America," said Saundra Pelletier, Chief Executive Officer of Evofem. a360 Media reaches 60 million unique digital visitors per month and another 27 million via print audiences.

Evofem Partners with a360 Media to Support Phexxi® Prescription Growth

Blue Apron

HTG Molecular Diagnostics

Tellurian

Short squeeze penny stocks to watch right now. The post Penny Stocks To Buy?

Penny Stocks To Buy? 4 Short Squeeze Stocks To Watch After CPI Data

SAN DIEGO , July 12, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) announced today that the Journal of Therapeutic Advances in Reproductive Health has published Mechanisms of action of currently available woman-controlled, vaginally administered, non-hormonal contraceptive products, a peer-reviewed article defining and reconfirming the mechanism of action (MOA) of Phexxi® (lactic acid, citric acid, potassium bitartrate). The Journal detailed and highlighted Phexxi's ability to maintain vaginal pH up to an hour before and during vaginal intercourse as a way of preventing pregnancy.

Phexxi® Mechanism of Action Article Published in the Journal of Therapeutic Advances in Reproductive Health

RedHill Biopharma

Alkaline Water Company Inc (The)

Here's what you need to know about trading penny stocks on July 12th The post What to Know About Buying Penny Stocks on July 12th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on July 12th

Uxin Ltd - ADR

Zomedica

Check these penny stocks out for your watchlist right now The post Best Penny Stocks to Buy Right Now? 3 to Watch  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Right Now? 3 to Watch

Fintel has ranked Evofem Biosciences as the next top gamma squeeze. Will Meade noticed.

Is Evofem Biosciences (EVFM) Stock the Next Big Squeeze?

Amarin Corporation Plc

DigitalBridge Group

What you need to know about trading penny stocks this month The post July Penny Stocks Buying Guide, 3 Things to Know appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

July Penny Stocks Buying Guide, 3 Things to Know

Creative Medical Technology Holdings

Ricebran Technologies

Are these penny stocks on your watchlist right now? The post Penny Stocks to Watch as June Comes to an End appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks to Watch as June Comes to an End

SAN DIEGO , June 30, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) announced today that the United States Patent and Trademark Office (USPTO) issued to the Company a Notice of Allowance for patent application 16/738,868 entitled, "Compositions and Methods for Enhancing the Efficacy of Contraceptive Microbicides" which covers the composition of matter of Phexxi® (lactic acid, citric acid, potassium bitartrate) and is expected to provide protection into at least 2033.  With the issuance of this patent, in the United States, Evofem will solely have the right to make, have made, market, and sell for any commercial purpose the composition of matter that comprises Phexxi.

Evofem Strengthens Phexxi® Intellectual Property with New Composition of Matter Patent From USPTO

Evofem Biosciences has already announced a strategic partnership. Here's why this new deal is great news for EVFM stock.

Evofem Biosciences (EVFM) Stock Remains in Spotlight With Contraception Access Deal

Agile Therapeutics

Femasys

Here's what you need to know about buying penny stocks on June 28th The post What to Know About Buying Penny Stocks on June 28th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on June 28th

Agreement Significantly Expands Access to Phexxi® for Millions of Women Seeking an FDA-Approved, Hormone-Free, On-Demand Option to Prevent Pregnancy Long-term Contract Adds to Growing List of Agreements with Payers Opening New and Significant Access to Phexxi Evofem Expects Increases in Phexxi Prescriptions and Significant Cost-Savings from Agreements SAN DIEGO , June 28, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it has reached an agreement with one of the nation's largest pharmacy benefit managers (PBMs) to ensure most women covered by this plan can fill their Phexxi® (lactic acid, citric acid, potassium bitartrate) prescriptions for pregnancy prevention, without restrictions such as prior authorization or step therapy. "This new agreement removes existing barriers, allowing women in the U.S. covered by this plan to fill their Phexxi prescriptions immediately," said Saundra Pelletier, Chief Executive Officer of Evofem.

Evofem Reaches Agreement with One of the Largest Pharmacy Benefit Managers in the U.S. for Access to Phexxi®

Evofem Biosciences is in the spotlight following the overturning of Roe v. Wade. Here's why EVFM stock is a name to watch.

EVFM Stock: Contraception Maker Evofem Biosciences Doubles After Roe Decision

Birth control drugmaker Evofem has attracted attention from investors amidst the setback for women's reproductive health.

Birth-control drugmaker Evofem Biosciences has spiked 240% since the Supreme Court's decision to overturn Roe vs. Wade

Shares of Evofem Biosciences Inc. EVFM, +155.45% soared 164.6% in trading on Monday in a rally that began Friday when the Supreme Court decision striking down Roe v. Wade was announced.

Evofem's stock is still soaring after Friday's Supreme Court decision

Acutus Medical

Cybin

Hillstream Biopharma

Penny stocks to watch with news The post Penny Stocks To Watch: Why EVFM, AGRX, CYBN, HILS & AFIB Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Watch: Why EVFM, AGRX, CYBN, HILS & AFIB Stock Are Moving

Cooper-Standard Holdings

The RealReal

Here's what you need to know about trading penny stocks on June 27th The post What to Know About Buying Penny Stocks on June 27th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on June 27th

Shares of Evofem Biosciences Inc. EVFM, +26.95% soared 30.6% in trading on Friday, hours after the Supreme Court decision striking down Roe v. Wade was announced.

Evofem's stock jumps 30% after Supreme Court decision on Roe v. Wade

Throughout 24,289 Acts of Intercourse, 101 Pregnancies were Reported with Typical Use of Phexxi in AMPOWER Post Hoc Analysis SAN DIEGO , June 16, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced results of a post hoc analysis of the registrational Phase 3 AMPOWER trial investigating the ability of Phexxi® (lactic acid, citric acid, and potassium bitartrate) to prevent pregnancy. In the analysis, Phexxi prevented 99% of pregnancies per act of intercourse.

Phexxi® Prevented 99% of Pregnancies Per Act of Intercourse in a Post Hoc Analysis of Phase 3 AMPOWER Clinical Trial Data

News for Evofem Biosciences Inc Stock (EVFM)